WO2003026635A3 - Procede ameliore de traitement du syndrome du diabete de type 2 chez les humains - Google Patents

Procede ameliore de traitement du syndrome du diabete de type 2 chez les humains Download PDF

Info

Publication number
WO2003026635A3
WO2003026635A3 PCT/US2002/018419 US0218419W WO03026635A3 WO 2003026635 A3 WO2003026635 A3 WO 2003026635A3 US 0218419 W US0218419 W US 0218419W WO 03026635 A3 WO03026635 A3 WO 03026635A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
syndrome
treating
type
opiates
Prior art date
Application number
PCT/US2002/018419
Other languages
English (en)
Other versions
WO2003026635A2 (fr
Inventor
Anton H Clemens
Original Assignee
Cpd Llc
Anton H Clemens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cpd Llc, Anton H Clemens filed Critical Cpd Llc
Publication of WO2003026635A2 publication Critical patent/WO2003026635A2/fr
Publication of WO2003026635A3 publication Critical patent/WO2003026635A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un procédé destiné à traiter un humain souffrant du syndrome du diabète de type 2 en lui administrant, selon un mode pharmaceutiquement efficace, une composition de médicament contenant un agent opioidergique comprenant des opiacés à activité agoniste ν, des opiacés à activité agoniste λ ou une combinaison de ces derniers, et un secretagogue d'insuline.
PCT/US2002/018419 2001-06-11 2002-06-11 Procede ameliore de traitement du syndrome du diabete de type 2 chez les humains WO2003026635A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/878,751 US20020045572A1 (en) 2000-08-15 2001-06-11 Method of treating the syndrome of type 2 diabetes in humans
US09/878,751 2001-06-11

Publications (2)

Publication Number Publication Date
WO2003026635A2 WO2003026635A2 (fr) 2003-04-03
WO2003026635A3 true WO2003026635A3 (fr) 2004-04-01

Family

ID=25372756

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/018419 WO2003026635A2 (fr) 2001-06-11 2002-06-11 Procede ameliore de traitement du syndrome du diabete de type 2 chez les humains

Country Status (2)

Country Link
US (1) US20020045572A1 (fr)
WO (1) WO2003026635A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528520B2 (en) 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
CA2628241C (fr) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
PT2001456E (pt) * 2006-04-04 2010-03-03 Emodys Gmbh Utilização de composições contendo antagonistas dos receptores opióides kappa no tratamento de distúrbios dissociativos
SI2724722T1 (sl) 2006-10-20 2017-07-31 Neurendo Pharma, Llc Postopek za obnovitev učinka inkretina
AU2008205229B2 (en) 2007-01-05 2014-03-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
KR20150116465A (ko) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
CA2702289A1 (fr) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Composes presentant une activite d'antagoniste de glucagon et d'agoniste du glp-1
CA2707861A1 (fr) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Antagonistes du glucagon
WO2009073627A1 (fr) * 2007-11-30 2009-06-11 The Research Foundation Of State University Of New York Biomarqueur de remplacement de combustible métabolique
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
NZ589847A (en) 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
EP2952202B1 (fr) 2008-06-17 2017-10-18 Indiana University Research and Technology Corporation Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
KR20120087875A (ko) 2009-06-16 2012-08-07 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Ｇｉｐ 수용체-활성 글루카곤 화합물
EP2512503A4 (fr) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Co-agonistes du récepteur du glucagon/glp-i
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
CA2797095A1 (fr) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Peptides de la superfamille des glucagons presentant une activite de recepteur nucleaire d'hormone
CA2797089A1 (fr) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Peptides de la superfamille du glucagon manifestant une activite de recepteur couple a une proteine g
WO2011163012A2 (fr) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Promédicaments peptidiques à base d'amides de la superfamille du glucagon
BR112013015389A2 (pt) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp análogo de glucagon exibindo atividade de receptor gip
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
KR20130017859A (ko) * 2011-08-12 2013-02-20 솔젠트 (주) 피니톨과 약물을 포함하는 당뇨병 치료용 병용제
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
EP2864351B1 (fr) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Analogues du glucagon présentant une activité sur le récepteur du gip
KR20140027594A (ko) * 2012-07-23 2014-03-07 씨지케이바이오 주식회사 항당뇨 및 항비만 활성을 갖는 약학 조성물
EP3215154B1 (fr) 2014-11-07 2020-01-29 Regents of the University of Minnesota Sels et compositions utiles pour le traitement de maladie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035608A1 (fr) * 1996-03-22 1997-10-02 The University Of Birmingham Traitement du diabete
WO2002100390A2 (fr) * 2001-06-11 2002-12-19 Cpd Llc Methode amelioree de traitement du syndrome des facteurs de risque de coronaropathie chez l'etre humain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035608A1 (fr) * 1996-03-22 1997-10-02 The University Of Birmingham Traitement du diabete
WO2002100390A2 (fr) * 2001-06-11 2002-12-19 Cpd Llc Methode amelioree de traitement du syndrome des facteurs de risque de coronaropathie chez l'etre humain

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
AHREN B: "Effects of [beta]-endorphin, met-enkephalin, and dynorphin A on basal and stimulated insulin secretion in the mouse", INTERNATIONAL JOURNAL OF PANCREATOLOGY 1989 UNITED STATES, vol. 5, no. 2, 1989, pages 165 - 178, XP008023242, ISSN: 0169-4197 *
BERKOW R.; FLETCHER A.J (EDS.).: "MERCK MANUAL OF DIAGNOSIS AND THERAPY (17th Ed.)", 1999, MERCK RESEARCH LABORATORIES, NEW JERSEY, XP002257951, 236240 *
BIOCHIMICA ET BIOPHYSICA ACTA. NETHERLANDS 19 SEP 1986, vol. 888, no. 2, 19 September 1986 (1986-09-19), pages 217 - 224, ISSN: 0006-3002 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; AHLGREN, GUNNAR: "Insulin -like action of morphine and certain morphine derivatives", XP002257953, accession no. STN Database accession no. 24:20275 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1982, GIUGLIANO D ET AL: "Impaired insulin secretion in human diabetes mellitus. The effect of naloxone-induced opiate receptor blockade", XP002257628, Database accession no. EMB-1982097228 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1987, GIUGLIANO D ET AL: "[beta]-Endorphin and islet hormone release in type-2 diabetes mellitus. The effects of normoglycemia, enkephalin, naloxone and somatostatin", XP002257952, Database accession no. EMB-1988087121 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 19 September 1986 (1986-09-19), VERSPOHL E J ET AL: "The significance of mu- and delta-receptors in rat pancreatic islets for the opioid-mediated insulin release.", XP002257627, Database accession no. NLM2874836 *
DIABETE ET METABOLISME 1987 FRANCE, vol. 13, no. 6, 1987, pages 618 - 624, ISSN: 0338-1684 *
DIABETES 1982 UNITED STATES, vol. 31, no. 4, 1982, pages 367 - 370 *
GOT I ET AL: "Medical treatment in diabetic patients with peripheral occlusive arterial disease", JOURNAL DES MALADIES VASCULAIRES 1993 FRANCE, vol. 18, no. 1, 1993, pages 30 - 36, XP008023367, ISSN: 0398-0499 *
GUPTA B ET AL: "GLUCOSE HOMEOSTATIS AND DRUGS ACTING ON CNS: INTERACTIONS WITH ANTIDIABETIC AGENTS", INDIAN JOURNAL OF PHARMACOLOGY, XX, XX, vol. 26, no. 3, 1994, pages 169 - 178, XP008022532, ISSN: 0253-7613 *
KHAWAJA X Z ET AL: "Increased sensitivity to insulin-releasing and glucoregulatory effects of dynorphin A1-13 and U 50488h in ob/ob versus lean mice", DIABETES 1990 UNITED STATES, vol. 39, no. 10, 1990, pages 1289 - 1297, XP008023244, ISSN: 0012-1797 *
LESLIE R D G ET AL: "SENSITIVITY TO ENKEPHALIN AS A CAUSE OF NON-INSULIN DEPENDENT DIABETES", LANCET, LITTLE, BROWM AND CO., BOSTON,, US, no. 8112, 17 January 1979 (1979-01-17), pages 341 - 343, XP008022453, ISSN: 0099-5355 *
SACHSE G ET AL: "OPIATES INFLUENCE ENDOCRINE PANCREAS SECRETION", DIABETOLOGIA, BERLIN, DE, vol. 21, no. 3, 1981, pages 444, XP008022526, ISSN: 0012-186X *
SKANDINAVISCHES ARCHIV FUER PHYSIOLOGIE (1930), 58, 153-72 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969288B2 (en) 2008-12-19 2015-03-03 Indiana University Research And Technology Corporation Amide based glucagon and superfamily peptide prodrugs
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists

Also Published As

Publication number Publication date
WO2003026635A2 (fr) 2003-04-03
US20020045572A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
WO2003026635A3 (fr) Procede ameliore de traitement du syndrome du diabete de type 2 chez les humains
JP4571236B2 (ja) ミューオピオイド作用薬およびカッパ−２オピオイド作用薬のサブ鎮痛用量共同投与による鎮痛性相乗作用を惹起する鎮痛組成物およびその製造方法
US6913760B2 (en) Drug delivery composition
WO2002013801A3 (fr) Methode amelioree permettant de traiter les facteurs de risque de cardiopathie ischemique chez les humains
US20030026838A1 (en) Tamper-proof narcotic delivery system
EP1105134A2 (fr) Sels et bases de la molecule de 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol destines a optimiser l'homeostase de la dopamine pendant l'administration d'analgesiques opioides
RU2005113996A (ru) Способы лечения боли введением антагониста фактора роста нервов и опиоидного анальгетика, и содержащие их композиции
JP2007246546A (ja) オピオイド鎮痛薬およびｎｍｄａアンタゴニストを含む局所用組成物
US20210196706A1 (en) Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
JP2004512260A5 (fr)
EP1430897A3 (fr) Formulations d'opioides à libération prolongée et controlée
WO2001041705A3 (fr) Traitement et prevention de vertiges et prurits
WO2001042207A3 (fr) Nouvelles methodes de traitement et de prevention de l'occlusion intestinale
WO2002013759A3 (fr) Methode de traitement du syndrome du diabete de type ii humain
RU2012124063A (ru) Лекарственная комбинация с теобромином и ее использование в лечении
US10226457B2 (en) Systems and methods for treating an opioid-induced adverse pharmacodynamic response
WO2011109743A2 (fr) Effets synergiques d'associations de buprenorphine et d'opioïdes pour le traitement des douleurs
US20100004275A1 (en) Agent for suppressing development of tolerance to narcotic analgesics
Mehendale et al. Clinical pharmacology of opioids: basic pharmacology
US20100317682A1 (en) Single Dosage Unit Including Opioid and Methylnaltrexone or Methylnaltrexone Salt
JP2005529106A5 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE CH CY DE DK FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP